Cargando…
Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies
The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a major roadblock for generating a broadly protective vaccine. Many experimental HIV-1 vaccine efforts are therefore aimed at eliciting broadly neutralizing antibodies (bNAbs) that are capable of neutra...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789800/ https://www.ncbi.nlm.nih.gov/pubmed/31362378 http://dx.doi.org/10.3390/vaccines7030076 |
_version_ | 1783458696972468224 |
---|---|
author | Brinkkemper, Mitch Sliepen, Kwinten |
author_facet | Brinkkemper, Mitch Sliepen, Kwinten |
author_sort | Brinkkemper, Mitch |
collection | PubMed |
description | The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a major roadblock for generating a broadly protective vaccine. Many experimental HIV-1 vaccine efforts are therefore aimed at eliciting broadly neutralizing antibodies (bNAbs) that are capable of neutralizing the majority of circulating HIV-1 strains. The envelope glycoprotein (Env) trimer on the viral membrane is the sole target of bNAbs and the key component of vaccination approaches aimed at eliciting bNAbs. Multimeric presentation of Env on nanoparticles often plays a critical role in these strategies. Here, we will discuss the different aspects of nanoparticles in Env vaccination, including recent insights in immunological processes underlying their perceived advantages, the different nanoparticle platforms and the various immunogenicity studies that employed nanoparticles to improve (neutralizing) antibody responses against Env. |
format | Online Article Text |
id | pubmed-6789800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67898002019-10-16 Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies Brinkkemper, Mitch Sliepen, Kwinten Vaccines (Basel) Review The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a major roadblock for generating a broadly protective vaccine. Many experimental HIV-1 vaccine efforts are therefore aimed at eliciting broadly neutralizing antibodies (bNAbs) that are capable of neutralizing the majority of circulating HIV-1 strains. The envelope glycoprotein (Env) trimer on the viral membrane is the sole target of bNAbs and the key component of vaccination approaches aimed at eliciting bNAbs. Multimeric presentation of Env on nanoparticles often plays a critical role in these strategies. Here, we will discuss the different aspects of nanoparticles in Env vaccination, including recent insights in immunological processes underlying their perceived advantages, the different nanoparticle platforms and the various immunogenicity studies that employed nanoparticles to improve (neutralizing) antibody responses against Env. MDPI 2019-07-29 /pmc/articles/PMC6789800/ /pubmed/31362378 http://dx.doi.org/10.3390/vaccines7030076 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Brinkkemper, Mitch Sliepen, Kwinten Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies |
title | Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies |
title_full | Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies |
title_fullStr | Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies |
title_full_unstemmed | Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies |
title_short | Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies |
title_sort | nanoparticle vaccines for inducing hiv-1 neutralizing antibodies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789800/ https://www.ncbi.nlm.nih.gov/pubmed/31362378 http://dx.doi.org/10.3390/vaccines7030076 |
work_keys_str_mv | AT brinkkempermitch nanoparticlevaccinesforinducinghiv1neutralizingantibodies AT sliepenkwinten nanoparticlevaccinesforinducinghiv1neutralizingantibodies |